Teriparatidacetat CAS:52232-67-4

Ansökningar &Fuction

Teriparatide is indicated for use in postmenopausal women with osteoporosis at a high risk for fracture or with a history of ostoporotic fracture, patienter med flera riskfaktorer för fraktur, och för patienter som har misslyckats eller är intoleranta mot annan tillgänglig osteoporosbehandling.

Teriparatide is also indicated to increase bone mass in men with primary or hypogonadal osteoporosis at high risk of fracture, patienter med flera riskfaktorer för fraktur, och för patienter som har misslyckats eller är intoleranta mot annan tillgänglig osteoporosbehandling.

Teriparatide is indicated as well for the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy.

Teriparatide should not be prescribed for patients who are at increased risks for osteosarcoma. This includes those with Paget’s Disease of bone or unexplained elevations of serum alkaline phosphate, open epiphysis, or prior radiation therapy involving the skeleton.